In July, Healio reported that “use of rivaroxaban after total hip or knee arthroplasty led to lower mortality risk and decreased reoperation rates due to infection or hematomas compared with low-molecular-weight heparin.” The original research was presented during the European Federation of National Associations of Orthopaedics and Traumatology (EFORT) Virtual Congress, June 30-July 2, 2021. Read the full article here.

Close Bitnami banner